| ||
| Targacept: Drug missed goal due to analysis error BusinessWeek Drug developer Targacept Inc. said Tuesday that further analysis showed an experimental asthma treatment failed one one of its goals in a clinical trial, contrary to what the company previously reported. Targacept shares lost 59 cents, or 12.2 percent, ... See all stories on this topic » | ||
| Asthma compound hits just one of two phase 2 goals, TRGT reanalysis shows MedCity News The asthma treatment Targacept (NASDAQ:TRGT) is developing actually did not perform as well in clinical trials as initially thought. Targacept last month released top-line phase 2 results for TC-6987 that showed the asthma compound met both goals in ... See all stories on this topic » | ||
| Targacept reports error in asthma study Triad Business Journal Targacept disclosed an error in the analysis of a potential asthma treatment, but says the candidate still holds promise. Targacept said an error in the analysis of a drug it recently studied as a potential treatment for asthma affected the results, ... See all stories on this topic » | ||
| Targacept Revises Results Of Exploratory Drug Study; Shares Slump Wall Street Journal Targacept Inc. (TRGT) said revised results of a recent Phase II study testing its TC-6987 drug candidate as an asthma treatment showed the drug in fact didn't meet one of its co-primary endpoints in the study. Shares of the drug developer slumped 10% ... See all stories on this topic » |
| ||
| Alternative medicine doesn't affect asthma care in children (HealthDay) -- Complementary and alternative medicine (CAM) is not associated with adherence to pediatric asthma treatment, according to a study published online April 9 in Pediatrics. Medical Xpress - latest medical... |
Tip: Use quotes ("like this") around a set of words in your query to match them exactly. Learn more.
Delete this alert.
Create another alert.
Manage your alerts.
No comments:
Post a Comment